Lincoln Pharmaceuticals Announces Final Dividend Recommendation for FY2026
Lincoln Pharmaceuticals has recommended a final dividend of Rs 1.80 per equity share, representing an 18% return on the face value of Rs 10 per share, for the financial year ended March 31, 2026. The recommendation is subject to approval from shareholders at the company's ensuing Annual General Meeting.
The pharmaceutical company, listed on the BSE under the symbol LINCOLN, has placed the dividend proposal before its members for final confirmation. This marks a continued commitment by the company to return value to its shareholders through dividend distributions.
Dividend Details at a Glance
- Dividend Amount: Rs 1.80 per equity share
- Dividend Rate: 18% on face value
- Face Value: Rs 10 per share
- Financial Year: ended March 31, 2026
- Status: Subject to shareholder approval at AGM
What This Means for Shareholders
If approved at the Annual General Meeting, eligible shareholders of Lincoln Pharmaceuticals will receive the final dividend for FY2026. The dividend recommendation reflects the company's financial performance during the fiscal year and underscores its dedication to rewarding investor confidence through consistent dividend payouts.
Investors and shareholders of Lincoln Pharmaceuticals should await further announcements regarding the record date and payment timeline once the dividend receives shareholder approval at the AGM.
About Lincoln Pharmaceuticals
Lincoln Pharmaceuticals operates in the pharmaceutical sector and is listed on the BSE. The company manufactures and supplies a range of pharmaceutical products and continues to serve markets across India with its diverse portfolio of healthcare solutions.
This dividend recommendation aligns with Lincoln Pharmaceuticals' ongoing strategy to maintain shareholder returns while investing in business growth initiatives.
Investors Advised to Monitor AGM Updates
Shareholders are encouraged to stay informed about the upcoming Annual General Meeting where the dividend proposal will be tabled for approval. Further clarity on the record date for determining dividend eligibility and the actual payment schedule will be communicated through official corporate announcements by Lincoln Pharmaceuticals.
As always, investors should review all corporate disclosures carefully before making any investment decisions. Dividend declarations are subject to shareholder approval and may be modified or withdrawn prior to the AGM.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. Investors are advised to conduct their own research or consult a qualified financial advisor before making investment decisions.